In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing <i>Enterobacter cloacae</i> and <i>Klebsiella pneumoniae</i> in Murine Pneumonia Model

• Main Authors: Mao Hagihara (Author), Hideo Kato (Author), Toshie Sugano (Author), Hayato Okade (Author), Nobuo Sato (Author), Yuichi Shibata (Author), Daisuke Sakanashi (Author), Jun Hirai (Author), Nobuhiro Asai (Author), Hiroyuki Suematsu (Author), Yuka Yamagishi (Author), Hiroshige Mikamo (Author)
• Format: Book
• Published: MDPI AG, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) have become global threats. CRE− and CPE− derived infections have been associated with high mortality due to limited treatment options. Nacubactam is a β-lactamase inhibitor and belongs to the new class of...